The gastrointestinal absorption of PRD-92 Ea, a new anti-allergy drug.
1 The absorption of PRD-92 Ea, a new anti-allergy drug, was studied in volunteer subjects. 2 The 14C-labelled drug was administered orally and the radioactivity measured in plasma, urine and faeces. 3 Mean peak plasma concentration was 3.3 micrograms/ml, with a concentration of over 1 micrograms/ml maintained 4 h after administration. 4 The mean plasma half-life (T 1/2) was 114 min. 5 The mean percentage recovery in the urine was 9.5%. 6 Oral administration leads to significant and sustained plasma concentrations, and the oral route should be suitable for drug evaluation in clinical practice.
D000328:Adult; D001578:Benzopyrans / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005243:Feces / Q000032:analysis; D005260:Female; D006207:Half-Life; D006634:Histamine H1 Antagonists / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D001578:Benzopyrans; D006634:Histamine H1 Antagonists